Glibenclamide in aneurysmal subarachnoid hemorrhage: a randomized controlled clinical trial

View More View Less
  • 1 Department of Neurosurgery, University of São Paulo, São Paulo, Brazil
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

OBJECTIVE

Glibenclamide has been shown to improve outcomes in cerebral ischemia, traumatic brain injury, and subarachnoid hemorrhage (SAH). The authors sought to evaluate glibenclamide’s impact on mortality and functional outcomes of patients with aneurysmal SAH (aSAH).

METHODS

Patients with radiologically confirmed aSAH, aged 18 to 70 years, who presented to the hospital within 96 hours of ictus were randomly allocated to receive 5 mg of oral glibenclamide for 21 days or placebo, in a modified intention-to-treat analysis. Outcomes were mortality and functional status at discharge and 6 months, evaluated using the modified Rankin Scale (mRS).

RESULTS

A total of 78 patients were randomized and allocated to glibenclamide (n = 38) or placebo (n = 40). Baseline characteristics were similar between groups. The mean patient age was 53.1 years, and the majority of patients were female (75.6%). The median Hunt and Hess, World Federation of Neurosurgical Societies (WFNS), and modified Fisher scale (mFS) scores were 3 (IQR 2–4), 3 (IQR 3–4), and 3 (IQR 1–4), respectively. Glibenclamide did not improve the functional outcome (mRS) after 6 months (ordinal analysis, unadjusted common OR 0.66 [95% CI 0.29–1.48], adjusted common OR 1.25 [95% CI 0.46–3.37]). Similar results were found for analyses considering the dichotomized 6-month mRS score (favorable score 0–2), as well as for the secondary outcomes of discharge mRS score (either ordinal or dichotomized), mortality, and delayed cerebral ischemia. Hypoglycemia was more frequently observed in the glibenclamide group (5.3%).

CONCLUSIONS

In this study, glibenclamide was not associated with better functional outcomes after aSAH. Mortality and delayed cerebral ischemia rates were also similar compared with placebo.

ABBREVIATIONS

aSAH = aneurysmal SAH; DCI = delayed cerebral ischemia; mFS = modified Fisher scale; mRS = modified Rankin Scale; SAH = subarachnoid hemorrhage; TBI = traumatic brain injury; WFNS = World Federation of Neurosurgical Societies.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):4458.

  • 2

    Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):14631469.

    • Search Google Scholar
    • Export Citation
  • 3

    Wijdicks EF, Kerkhoff H, van Gijn J. Long-term follow-up of 71 patients with thunderclap headache mimicking subarachnoid haemorrhage. Lancet. 1988;2(8602):6870.

    • Search Google Scholar
    • Export Citation
  • 4

    Vivancos J, Gilo F, Frutos R, Maestre J, García-Pastor A, Quintana F, et al. Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment. Neurologia. 2014;29(6):353370.

    • Search Google Scholar
    • Export Citation
  • 5

    Ducruet AF, Gigante PR, Hickman ZL, Zacharia BE, Arias EJ, Grobelny BT, et al. Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2010;30(4):676688.

    • Search Google Scholar
    • Export Citation
  • 6

    Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;(3):CD000277.

    • Search Google Scholar
    • Export Citation
  • 7

    Patel AD, Gerzanich V, Geng Z, Simard JM. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol. 2010;69(12):11771190.

    • Search Google Scholar
    • Export Citation
  • 8

    Sheth KN, Kimberly WT, Elm JJ, Kent TA, Yoo AJ, Thomalla G, et al. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014;21(1):4351.

    • Search Google Scholar
    • Export Citation
  • 9

    Simard JM, Geng Z, Woo SK, Ivanova S, Tosun C, Melnichenko L, Gerzanich V. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2009;29(2):317330.

    • Search Google Scholar
    • Export Citation
  • 10

    Tosun C, Kurland DB, Mehta R, Castellani RJ, deJong JL, Kwon MS, et al. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke. 2013;44(12):35223528.

    • Search Google Scholar
    • Export Citation
  • 11

    Kimberly WT, Battey TW, Pham L, Wu O, Yoo AJ, Furie KL, et al. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014;20(2):193201.

    • Search Google Scholar
    • Export Citation
  • 12

    Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016;15(11):11601169.

    • Search Google Scholar
    • Export Citation
  • 13

    Khalili H, Derakhshan N, Niakan A, Ghaffarpasand F, Salehi M, Eshraghian H, et al. Effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries: a randomized double-blind placebo-controlled clinical trial. World Neurosurg. 2017;101:130136.

    • Search Google Scholar
    • Export Citation
  • 14

    Boggs DH, Simard JM, Steven A, Mehta MP. Potential of glyburide to reduce intracerebral edema in brain metastases. Expert Rev Neurother. 2014;14(4):379388.

    • Search Google Scholar
    • Export Citation
  • 15

    da Costa BBS, Windlin IC, Koterba E, Yamaki VN, Rabelo NN, Solla DJF, et al. Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial. Trials. 2019;20(1):413.

    • Search Google Scholar
    • Export Citation
  • 16

    Shen J, Shen J, Zhu K, Zhou H, Tian H, Yu G. Efficacy of statins in cerebral vasospasm, mortality, and delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of randomized controlled trials. World Neurosurg. 2019;131:e65e73.

    • Search Google Scholar
    • Export Citation
  • 17

    Kurland DB, Tosun C, Pampori A, Karimy JK, Caffes NM, Gerzanich V, Simard JM. Glibenclamide for the treatment of acute CNS injury. Pharmaceuticals (Basel). 2013;6(10):12871303.

    • Search Google Scholar
    • Export Citation
  • 18

    Chen M, Dong Y, Simard JM. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci. 2003;23(24):85688577.

    • Search Google Scholar
    • Export Citation
  • 19

    Gerzanich V, Stokum JA, Ivanova S, Woo SK, Tsymbalyuk O, Sharma A, et al. Sulfonylurea receptor 1, transient receptor potential cation channel subfamily M member 4, and KIR6.2:role in hemorrhagic progression of contusion. J Neurotrauma. 2019;36(7):10601079.

    • Search Google Scholar
    • Export Citation
  • 20

    Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. 2005;36(8):16271632.

    • Search Google Scholar
    • Export Citation
  • 21

    van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, Rinkel GJ. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36(5):10111015.

    • Search Google Scholar
    • Export Citation
  • 22

    Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J, Stroes ES, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab. 2009;29(8):14441453.

    • Search Google Scholar
    • Export Citation
  • 23

    Eisenberg HM, Shenton ME, Pasternak O, Simard JM, Okonkwo DO, Aldrich C, et al. Magnetic resonance imaging pilot study of intravenous glyburide in traumatic brain injury. J Neurotrauma. 2020;37(1):185193.

    • Search Google Scholar
    • Export Citation
  • 24

    Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618625.

    • Search Google Scholar
    • Export Citation
  • 25

    Thompson EM, Pishko GL, Muldoon LL, Neuwelt EA. Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. Neoplasia. 2013;15(5):535543.

    • Search Google Scholar
    • Export Citation
  • 26

    Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13(7):666675.

    • Search Google Scholar
    • Export Citation
  • 27

    Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619624.

    • Search Google Scholar
    • Export Citation
  • 28

    Pergakis M, Badjatia N, Chaturvedi S, Cronin CA, Kimberly WT, Sheth KN, Simard JM. BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema. Expert Opin Investig Drugs. 2019;28(12):10311040.

    • Search Google Scholar
    • Export Citation
  • 29

    Zafardoost P, Ghasemi AA, Salehpour F, Piroti C, Ziaeii E. Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma. Trauma Mon. 2016;21(5):e25113.

    • Search Google Scholar
    • Export Citation
  • 30

    Zweckberger K, Hackenberg K, Jung CS, Hertle DN, Kiening KL, Unterberg AW, Sakowitz OW. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neuroscience. 2014;272:199206.

    • Search Google Scholar
    • Export Citation
  • 31

    Jiang B, Li L, Chen Q, Tao Y, Yang L, Zhang B, et al. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl Stroke Res. 2017;8(2):183193.

    • Search Google Scholar
    • Export Citation
  • 32

    Jha RM, Bell J, Citerio G, Hemphill JC, Kimberly WT, Narayan RK, et al. Role of sulfonylurea receptor 1 and glibenclamide in traumatic brain injury: a review of the evidence. Int J Mol Sci. 2020;21(2):409.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 147 147 147
Full Text Views 41 41 41
PDF Downloads 48 48 48
EPUB Downloads 0 0 0